These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 16249270)

  • 1. Efaproxiral: a radiation enhancer used in brain metastases from breast cancer.
    Charpentier MM
    Ann Pharmacother; 2005 Dec; 39(12):2038-45. PubMed ID: 16249270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases.
    Suh JH; Stea B; Nabid A; Kresl JJ; Fortin A; Mercier JP; Senzer N; Chang EL; Boyd AP; Cagnoni PJ; Shaw E
    J Clin Oncol; 2006 Jan; 24(1):106-14. PubMed ID: 16314619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxiral (Efaproxyn) plus whole-brain radiation therapy for brain metastases.
    Scott C; Suh J; Stea B; Nabid A; Hackman J
    Am J Clin Oncol; 2007 Dec; 30(6):580-7. PubMed ID: 18091051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efaproxiral (Allos Therapeutics).
    Kolman A
    IDrugs; 2003 Aug; 6(8):795-801. PubMed ID: 12917776
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of efaproxiral in metastatic brain tumors.
    Engel RH; Kaklamani VG
    Expert Rev Anticancer Ther; 2006 Apr; 6(4):477-85. PubMed ID: 16613536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
    Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Whole-brain radiotherapy with or without efaproxiral for the treatment of brain metastases: Determinants of response and its prognostic value for subsequent survival.
    Stea B; Suh JH; Boyd AP; Cagnoni PJ; Shaw E;
    Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1023-30. PubMed ID: 16446056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group Recursive Partitioning Analysis Brain Metastases Database.
    Shaw E; Scott C; Suh J; Kadish S; Stea B; Hackman J; Pearlman A; Murray K; Gaspar L; Mehta M; Curran W; Gerber M
    J Clin Oncol; 2003 Jun; 21(12):2364-71. PubMed ID: 12805339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased oxygenation of intracranial tumors by efaproxyn (efaproxiral), an allosteric hemoglobin modifier: In vivo EPR oximetry study.
    Hou H; Khan N; O'Hara JA; Grinberg OY; Dunn JF; Abajian MA; Wilmot CM; Demidenko E; Lu S; Steffen RP; Swartz HM
    Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1503-9. PubMed ID: 15817356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efaproxiral: a novel radiation sensitiser.
    Suh JH
    Expert Opin Investig Drugs; 2004 May; 13(5):543-50. PubMed ID: 15155129
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Radiation sensitization with redox modulators: a promising approach.
    Rosenberg A; Knox S
    Int J Radiat Oncol Biol Phys; 2006 Feb; 64(2):343-54. PubMed ID: 16414370
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of Efaproxyn (efaproxiral) on subcutaneous RIF-1 tumor oxygenation and enhancement of radiotherapy-mediated inhibition of tumor growth in mice.
    Hou H; Khan N; Grinberg OY; Yu H; Grinberg SA; Lu S; Demidenko E; Steffen RP; Swartz HM
    Radiat Res; 2007 Aug; 168(2):218-25. PubMed ID: 17638413
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efaproxiral red blood cell concentration predicts efficacy in patients with brain metastases.
    Stea B; Shaw E; Pintér T; Hackman J; Craig M; May J; Steffen RP; Suh JH
    Br J Cancer; 2006 Jun; 94(12):1777-84. PubMed ID: 16773073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of patients with newly diagnosed glioblastoma multiforme treated with RSR13 and radiotherapy: results of a phase II new approaches to brain tumor therapy CNS consortium safety and efficacy study.
    Kleinberg L; Grossman SA; Carson K; Lesser G; O'Neill A; Pearlman J; Phillips P; Herman T; Gerber M
    J Clin Oncol; 2002 Jul; 20(14):3149-55. PubMed ID: 12118029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
    Medina PJ; Goodin S
    Clin Ther; 2008 Aug; 30(8):1426-47. PubMed ID: 18803986
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Clinical analysis of 67 patients with brain metastases from breast cancer].
    He J; Feng FY; Xing PY; Wang XY; Zhang P
    Ai Zheng; 2005 Dec; 24(12):1527-30. PubMed ID: 16351807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain metastases in breast cancer: prognostic factors and management.
    Lee SS; Ahn JH; Kim MK; Sym SJ; Gong G; Ahn SD; Kim SB; Kim WK
    Breast Cancer Res Treat; 2008 Oct; 111(3):523-30. PubMed ID: 17990100
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motexafin gadolinium: a clinical review of a novel radioenhancer for brain tumors.
    Khuntia D; Mehta M
    Expert Rev Anticancer Ther; 2004 Dec; 4(6):981-9. PubMed ID: 15606327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efaproxiral: should we hold our breath?
    Sneed PK
    J Clin Oncol; 2006 Jan; 24(1):13-5. PubMed ID: 16314614
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.